How practical are adaptive designs likely to be for confirmatory trials?

Biometrical Journal

Volumn 48, Issue 4, 2006, Pages 644-649

  Gould, A Lawrence ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adaptive seamless design; Adaptive tests; Closure principle; Combination tests; Confirmation; Estimation; Hypotheses selection; Multiple testing; Planning

Indexed keywords

ADAPTIVE DESIGNS; ADAPTIVE SEAMLESS DESIGN; ADAPTIVE TESTS; CLOSURE PRINCIPLE; COMBINATION TEST; CONFIRMATION; HYPOTHESIS SELECTION; MULTIPLE TESTING; PHASE II; SEAMLESS DESIGN;

EID: 33748539739     PISSN: 03233847     EISSN: 15214036     Source Type: Journal    
DOI: 10.1002/bimj.200610242     Document Type: Review

References (66)

1. Bauer, P and Köhne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50, 1029-1041.
2. Bechhofer, R. E., Gupta, S. S. and Sobel, M. (1986). Modern statistical selection, Part 1. American Sciences Press, Syracuse.
3. Bretz, F., Schmidli, H., König, F., Racine, A. and Maurer, W. (2006). Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: General concepts. Biometrical Journal 48, 623-634.
4. Brannath, W., König, F. and Bauer, P. (2006). Estimation in flexible two stage designs. Statistics in Medicine, in press.
5. EMEA (2006). Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan (Draft 3/23/2006). EMEA (European Medicines Agency). Committee for medicinal products for human use.
6. Gibbons, J. D., Olkin, I. and Sobel, M. (1999). Selecting and ordering populations: a new statistical methodology. Society for Industrial and Applied Mathematics (SIAM), Philadephia.
7. Grieve, A. P. and Krams, M. (2005). ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clinical Trials 2, 340-351.
8. Inoue, L. Y. T., Thall, P. F. and Berry, D. A. (2002). Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58, 823-831.
9. Jennison, C. and Turnbull, B. W. (2006). Adaptive and nonadaptive group sequential designs. Biometrika 93, 1-21.
10. Krams, M., Lees, K. R. and Berry, D. A. (2005). The past is the future. Innovative designs in acute stroke therapy trials. Stroke 36, 1341-1347.
11. Krams, M., Lees, K. R., Hacke, W., Grieve, A. P., Orgogozo, J. M. and Ford, G. A. (2003). Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke 34, 2543-2548.
12. Liu, Q. and Pledger, G. W. (2005). Phase 2 and 3 combination designs to accelerate drug development. Journal of the American Statistical Association 100, 493-502.
13. Marcus, R., Peritz, E., and Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63, 655-660.
14. Schmidli, H., Bretz, F., Racine, A. and Maurer, W. (2006). Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: Applications and practical considerations. Biometrical Journal 48, 635-643.
15. Sheiner, L. B. (1997). Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics 61, 275-291.
16. Aickin, M. (2001). Randomization, balance, and the validity and efficiency of design-adaptive allocation methods. Journal of Statistical Planning and Inference 94, 97-119.
17. Andersen, J. S. (1996). Clinical trial designs - Made to order. Journal of Biopharmaceutical Statistics 6, 515-522.
18. Anderson, K. M. (2004). Optimized adaptive versus optimized group sequential 2-stage designs. ASA Proceedings of the Joint Statistical Meetings. American Statistical Association, 571-578.
19. Bandyopadhyay, U. and Biswas, A. (2001). Adaptive designs for normal responses with prognostic factors. Biometrika 88, 409-419.
20. Bandyopadhyay, U. and Biswas, A. (2003). Interval estimation in adaptive allocations using point estimates. Calcutta Statistical Association Bulletin 54, 31-44.
21. Bauer, P. and Kieser, M. (1999). Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 18, 1833-1848.
22. Bekele, B. N. and Thall, P. F. (2004). Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. Journal of the American Statistical Association 99, 26-35.
23. Bekele, B. N. and Shen, Y. (2005). A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II. dose-finding trial. Biometrics 61, 343-354.
24. Bischoff, W. and Miller, F. (2005). Adaptive two-stage test procedures to find the best treatment in clinical trials. Biometrika 92, 197-212.
25. Biswas, A. and Chaudhuri, P. (2002). An efficient design for model discrimination and parameter estimation in linear models. Biometrika 89, 709-718.
26. Biswas, A. and Angers, J. F. O. (2002). A Bayesian adaptive design in clinical trials for continuous responses. Statistica Neerlandica 56, 400-414.
27. Biswas, A. and Basu, A. (2001). Robust adaptive designs in clinical trials for continuous responses. Sankhya, Series B63, 27-42.
28. Brannath, W., Bauer, P., Maurer, W. and Posch, M. (2003). Sequential tests for the noninferiority and superiority. Biometrics 59, 106-114.
29. Chang, M. and Chow, S. C. (2005). A hybrid Bayesian adaptive design for dose response trials. Journal of Biopharmaceutical Statistics 15, 677-691.
30. Cheng, Y. and Shen, Y. (2004). Bayesian adaptive designs for clinical trials. ASA Proceedings of the Joint Statistical Meetings. American Statistical Association, 300-307.
31. Cheng, Y. and Berry, D. A. (2004). Optimal adaptive randomized designs for clinical trials. ASA Proceedings of the Joint Statistical Meetings. American Statistical Association, 206-212.
32. Cheng, Y. and Shen, Y. (2005). Bayesian adaptive designs for clinical trials. Biometrika 92, 633-646.
33. Fan, J. (1992). Design-adaptive nonparametric regression. Journal of the American Statistical Association 87, 998-1004.
34. Feder, P. I., Hobson, D. W., Olson, C. T., Joiner, R. L. and Matthews, M. C. (1992). Statistical design considerations for stagewise, adaptive dose allocation in dose-response studies. In K. E. Peace (Ed.), Biopharmaceutical Sequential Statistical Applications. Marcel Dekker Inc, New York, 37-86.
35. Hardwick, J. and Stout, Q. F. (2002). Optimal few-stage designs. Journal of Statistical Planning and Inference 104, 121-145.
36. Hill, N. J., Padmanabhan, A. R. and Puri, M. L. (1988). Adaptive nonparametric procedures and applications. Applied Statistics 37, 205-218.
37. Hochberg, Y. (1986). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 73, 800-802.
38. Hommel, G., Lindig, V. and Faldum, A. (2005). Two-stage adaptive designs with correlated test statistics. Journal of Biopharmaceutical Statistics 15, 613-623.
39. Kelly, P. J., Stallard, N. and Todd, S. (2005). An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15, 641-658.
40. Koyama, T., Sampson, A. R. and Gleser, L. J. (2005). A calculus for design of two-stage adaptive procedures. Journal of the American Statistical Association 100, 197-203.
41. Lehmacher, W. and Wassmer, G. (1999). Adaptive sample size calculations in group sequential trials. Biometrics 55, 1286-1290.
42. Li, G., Shih, W. J., and Wang, Y. (2005). Two-stage adaptive design for clinical trials with survival data. Journal of Biopharmaceutical Statistics 15, 707-718.
43. Lin, Y. and Shih, W. J. (2004). Adaptive two-stage designs for single-arm phase IIa cancer clinical trials. Biometrics 60, 482-490.
44. Liu, Q. and Chi, G. Y. H. (2001). On sample size and inference for two-stage adaptive designs. Biometrics 57, 172-177.
45. Liu, Q., Proschan, M. A. and Pledger, G. W. (2002). A unified theory of two-stage adaptive designs. Journal of the American Statistical Association 97, 1034-1041.
46. Liu, Q., Anderson, K. M. and Pledger, G. W. (2004). Benefit-risk evaluation of multi-stage adaptive designs. Sequential Analysis 23, 317-331.
47. Müller, H. H. and Schäfer, H. (2001). Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics 57, 886-891.
48. Posch, M. and Bauer, P. (1999). Adaptive two stage designs and the conditional error function. Biometrical Journal 41, 689-696.
49. Posch, M. and Bauer, P. (2000). Interim analysis and sample size reassessment. Biometrics 56, 1170-1176.
50. Posch, M., Bauer, P. and Brannath, W. (2003). Issues in designing flexible trials. Statistics in Medicine 22, 953-969.
51. Proschan, M. A. and Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51, 1315-1324.
52. Rosenberger, W. F. and Lachin, J. M. (1993). The use of response-adaptive designs in clinical trials. Controlled Clinical Trials 14, 471-484.
53. Rosenberger, W. F. (1996). New directions in adaptive designs. Statistical Science 11, 137-149.
54. Rosenberger, W. F., Stallard, N., Ivanova, A., Harper, C. N. and Ricks, M. L. (2001). Optimal adaptive designs for binary response trials. Biometrics 57, 909-913.
55. Rosenberger, W. F., Vidyashankar, A. N. and Agarwal, D. K. (2001). Covariate-adjusted response-adaptive designs for binary response. Journal of Biopharmaceutical Statistics 11, 227-236.
56. Schwabe, R. (1991). Adaptive design in the one-way layout. Journal of Statistical Planning and Inference 28, 319-338.
57. Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751-754.
58. Simon, R. (1977). Adaptive treatment assignment methods and clinical trials. Biometrics 33, 743-749.
59. Thall, P. F., Inoue, L. Y. T. and Martin, T. G. (2002). Adaptive decision making in a lymphocyte infusion trial. Biometrics 58, 560-568.
60. Thall, P. F., Millikan, R. E., Mueller, P. and Lee, S. J. (2003). Dose-finding with two agents in phase I oncology trials. Biometrics 59, 487-496.
61. Thall, P. F. and Cook, J. D. (2004). Dose-finding based on efficacy? Toxicity trade-offs. Biometrics 60, 684-693.
62. Wassmer, G. (2003). Data-driven analysis strategies for proportion studies in adaptive group sequential test designs. Journal of Biopharmaceutical Statistics 13, 585-603.
63. Wust, K. and Kieser, M. (2005). Monitoring continuous long-term outcomes in adaptive designs. Communications in Statistics: Simulation and Computation 34, 321-341.
64. Yao, Q. and Wei, L. J. (1996). Play the winner for phase II/III clinical trials (Disc: pp. 2455-2458). Statistics in Medicine 15, 2413-2423.
65. Yin, G. and Shen, Y. (2005). Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics 61, 362-369.
66. Yin, G. and Shen, Y. (2005). Self-designing trial combined with classical group sequential monitoring. Journal of Biopharmaceutical Statistics 15, 667-675.